Here are the 424B prospectus supplements from Omeros Corporation (OMER) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow OMER and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OMER filings page.
Omeros Corporation launched an at-the-market offering of up to $150,000,000 of common stock under a Controlled Equity Offering agreement with Cantor Fitzgerald as sales agent. Shares may be sold from time to time on Nasdaq or through negotiated transactions, with Cantor earning up to 3.0% of the gross sales price per share.
Proceeds will be used for general corporate purposes, including clinical and pre-clinical development, commercialization activities, working capital, potential debt repayment, acquisitions or investments, and other capital expenditures. As context, based on the November 13, 2025 closing price of $6.28, the company illustrates a maximum of 23,885,350 shares. Omeros reported 70,073,622 shares outstanding as of September 30, 2025, and provides an example showing 93,958,972 shares if the full amount were sold at that price. Estimated offering expenses are approximately $300,000.